817 completed, 281 unknown, 180 recruiting, 167 terminated. 1645 Phase 3, 260 Phase 2.
Follow Intestinal Diseases: new trials by email Literature Review of Intestinal Diseases trials Research Report on Intestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Piperacillin/Tazobactam Versus Ceftriaxone and Metronidazole for Children With Perforated Appendicitis Piperacillin/Tazobactam, Ceftriaxone + Metronidazole - Appendicitis Perforated, Appendectomy, Laparoscopic | Phase 3 | Not yet recruiting | McMaster Children's Hospital | 180 | 2027-04-01 | 2026-10-09 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2027-01-04 | 2026-11-05 |
| Nitazoxanide for Treatment of Cryptosporidium in Children Nitazoxanide, Placebo - Cryptosporidiosis | Phase 3 | Not yet recruiting | Johns Hopkins Bloomberg School of Public Health | 480 | 2026-12-30 | 2026-09-28 |
| Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders Rifaximin (drug), Placebo - Bloating, Rifaximin | Phase 3 | Not yet recruiting | Mahidol University | 78 | 2026-12-01 | 2026-10-27 |
| Effects of Butyrate Enemas on Postoperative Intestinal Motility Disorders in Hirschsprung's Disease Sodium Butyrate, routine management - Hirschsprung's Disease | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 58 | 2026-11-01 | 2026-09-10 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil - Colorectal Cancer | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 368 | 2026-11-01 | 2026-11-03 |
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer node-sparing modified short-course radiotherapy, standard short-course radiotherapy - Rectal Cancer | Phase 3 | Not yet recruiting | Sir Run Run Shaw Hospital | 210 | 2026-10-25 | 2026-10-28 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Recruiting | Tanta University | 44 | 2026-10-25 | 2026-11-09 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer DWP14012 40mg (Fexuprazan), Lansoprazole 30mg - Gastric Ulcer | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 384 | 2026-10-15 | 2026-07-28 |
| Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer Fruquintinib Combined With Capecitabine, Follow-up observation - Colorectal Cancer | Phase 3 | Not yet recruiting | West China Hospital | 140 | 2026-10-08 | 2026-10-21 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-11-03 |
| Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers Arm A: DC vaccination, Arm B: Placebo vaccination - Lynch Syndrome | Phase 3 | Not yet recruiting | Radboud University Medical Center | 372 | 2026-10-01 | 2026-05-27 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer Dostarlimab - Neoplasms, Rectal | Phase 3 | Not yet recruiting | GlaxoSmithKline | 90 | 2026-09-17 | 2026-08-03 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-08-25 | 2026-09-21 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
Showing 20 of 1645. Sign in to see all of them.
Colorectal Neoplasms (522) · Rectal Neoplasms (245) · Crohn Disease (238) · Colonic Neoplasms (237) · Colitis, Ulcerative (223) · Inflammatory Bowel Diseases (97) · Irritable Bowel Syndrome (71) · Neoplasm Metastasis (54) · Stomach Ulcer (43) · Neoplasms (42) · Short Bowel Syndrome (35) · Diarrhea (34) · Gastrointestinal Diseases (30) · Duodenal Ulcer (27)
Digestive System Diseases (1621) · Gastrointestinal Diseases (1615) · Colonic Diseases (970) · Neoplasms by Site (808) · Digestive System Neoplasms (805) · Intestinal Neoplasms (800) · Gastrointestinal Neoplasms (799) · Neoplasms (782) · Rectal Diseases (736) · Gastroenteritis (552) · Inflammatory Bowel Diseases (363) · Pathological Conditions, Signs and Symptoms (303) · Colorectal Neoplasms (285) · Colitis (220)
Fluorouracil (185) · Leucovorin (169) · Oxaliplatin (151) · Capecitabine (117) · Bevacizumab (113) · Irinotecan (95) · Cetuximab (59) · Mesalamine (54) · Folfox protocol (52) · Adalimumab (43) · Infliximab (29) · Radiotherapy (28) · Drug Therapy (25) · Lansoprazole (25) · vedolizumab (24)
Takeda (44) · Sun Yat-sen University (30) · Janssen Research & Development, LLC (29) · AbbVie (28) · Shire (26) · Fudan University (24) · AstraZeneca (22) · Alliance for Clinical Trials in Oncology (21) · Hoffmann-La Roche (21) · Bausch Health Americas, Inc. (20) · National Cancer Institute (NCI) (18) · Sixth Affiliated Hospital, Sun Yat-sen University (17) · Assistance Publique - Hôpitaux de Paris (16) · Pfizer (16) · Abbott (15)
United States (545) · France (321) · Canada (305) · Germany (300) · China (291) · Italy (271) · Belgium (267) · United Kingdom (261) · Poland (247) · Spain (242) · Netherlands (218) · Japan (202) · South Korea (202) · Australia (192) · Israel (181)
PMID 36306483, PMID 29380251, PMID 32445184, PMID 31268130, PMID 33356421, PMID 37368103, PMID 40357993, PMID 30679026, PMID 31378656, PMID 19735233, PMID 20195905, PMID 20526599, PMID 21997132, PMID 26893500, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32085892, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36208720, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37310167, PMID 37402275, PMID 37560161, PMID 38096402, PMID 38310565, PMID 38425446, PMID 40013523, PMID 41264726, PMID 41763462, PMID 21129076, PMID 25996351, PMID 26049686, PMID 26563167, PMID 27959607, PMID 28467869
2023 (39), 2017 (25), 2016 (20), 2025 (17), 2015 (16), 2018 (15), 2019 (13), 2014 (12), 2004 (8), 2009 (8), 2008 (7), U10CA031946 (7), 2005 (6), U10CA012027 (5), U10CA021115 (5)